Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFFICIENT: Insulin Icodec vs Basal Insulin Analogues in Type 2 Diabetes
NCT07112339Phase 4Recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2025
- Primary completion
- Mar 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 4 trial of insulin icodec in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Aug 2025; status: recruiting.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07112339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07112339.